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Abstract
Introduction
The pros and cons for implementing protocol biopsies (PB) after kidney transplantation are
still a matter of debate. We aimed to address the frequency of pathological findings in PB, to
analyze their impact on long-term graft survival (GS) and to analyze the risk factors predict-
ing an abnormal histology.
Methods
We analyzed 946 kidney PB obtained at a median time of 6.5 (±2.9) months after transplan-
tation. Statistics included comparison between groups, Kaplan-Meier and multinomial logis-
tic regression analysis.
Results and Discussion
PB diagnosis were: 53.4% normal; 46% IFTA; 12.3% borderline and 4.9% had subclinical
acute rejection (SCAR). Inflammation had the strongest negative impact on GS. Therefore
we split the cases into: “normal without inflammation”, “normal with inflammation”, “IFTA
without inflammation”, “IFTA with inflammation” and “rejection” (including SCAR and border-
line). 15-year GS in PB diagnosed normal with inflammation was significantly decreased in
a similar fashion as in rejection cases. Among normal biopsies, inflammation increased sig-
nificantly the risk of 15-y graft loss (P = 0.01). Variables that predicted an abnormal biopsy
were proteinuria, previous AR and DR-mismatch.
Conclusion
We conclude that inflammation in normal PB is associated with a significantly lower 15-y
GS, comparable to rejection or IFTA with inflammation.
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Introduction
The pros and cons for implementing protocol biopsies (PB) after kidney transplantation are
still a matter of debate. Although its use in the context of randomized controlled trials is gener-
ally approved, a concrete benefit in the routine follow-up of kidney transplant patients is yet to
be fully demonstrated. Therefore, graft function is usually monitored by serum creatinine, esti-
mated glomerular filtration rate and proteinuria, whereas a kidney biopsy is indicated to ascer-
tain the cause of graft dysfunction. The potential benefit of recognizing unexpected
pathological patterns in well-functioning kidneys early enough may have an impact on graft
survival (GS), as suggested almost two decades ago by Rush. [1] The treatment of acute rejec-
tion (AR) diagnosed by protocol biopsies (i.e. subclinical acute rejection, SCAR) was translated
into a better survival, [2] although these results could not be reproduced in larger studies in the
era of modern immunosuppression. [3,4] Furthermore, due to improvements in immunosup-
pression, the incidence of clinical AR has decreased and the reported rate of SCAR is very low.
For these reasons histological monitoring has been recommended only for patients at high risk
for developing AR, such as cross-match positive, ABO-mismatched, highly immunized or
those with delayed graft function. [5]
Long-term kidney GS has not increased remarkably in the past decade and underlying pro-
cesses of both immunological and non-immunological nature could be a reason for this. [6]
The role of inflammation both on indication biopsies and protocol biopsies is a well-known
risk factor for kidney graft loss of immunological nature, but this negative impact has been
described in association to interstitial fibrosis and tubular atrophy (IFTA) or other features
compatible with AR. [7,8] However, the frequency and relevance of the subtle nonspecific
inflammation in the absence of other histopathological changes is not clear. The histological
monitoring of the kidney grafts opens a window for tailoring treatment, such as minimization
of immunosuppression in cases of normal histology. Although this measure could diminish the
impact of calcineurin inhibitor-related nephrotoxicity or the adverse effects secondary to the
use of steroids, lately there has been increasing concern about the negative impact of the mini-
mization on the development of de novo donor specific antibodies leading to chronic rejection.
[9]
In the present study we aimed to address the frequency of pathological findings in a large
material of protocol biopsies in two European transplant centers, to analyze their impact on
long-term graft survival (GS) and to analyze the risk factors predicting an abnormal histology
which might help target patients who could get a benefit from this procedure.
Material and Methods
Patient population
Altogether 946 cross match negative ABO compatible kidney transplant patients (KT) from
Helsinki University Hospital and Bellvitge University Hospital were biopsied by protocol from
January 1994 to December 2011. Candidates for PB gave written consent for this procedure
and further histological analysis. They should have had a stable serum creatinine concentration
and uneventful follow-up during one month previous to the biopsy. Histological monitoring of
kidney allografts with protocol biopsies is part of our regular follow-up protocol and for this
reason neither the Helsinki University Hospital nor the Bellvitge University Hospital ethical
committees require permission for this type of research. Time for PB slightly changed over the
years, aimed at 6 months post transplantation in the majority of the cases, but for a short
period we performed at 3 months (only in Helsinki) and in the last years at 12 months. Only
one protocol biopsy per patient was considered and follow-up biopsies were not included.
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Urinary tract infection was ruled out. Recipients of multiple organs were not considered. We
discarded 20 cases because of insufficient follow-up data and 23 cases because of insufficient
histological material, leaving a total of 903 biopsies to be included in this analysis (N = 480
from Helsinki and N = 423 from Bellvitge).
Clinical data included donor and recipient demographics, type and number of transplant,
panel reactive antibodies (PRA), A-, B- and DR- mismatch, occurrence of delayed graft func-
tion (DGF), cold ischemia time (CIT), clinical rejection episodes before PB (AR), time from
transplantation to protocol biopsy, serum creatinine, estimated GFR with CKD-EPI [10],
immunosuppression at the time of PB, proteinuria at biopsy time and during the follow up as
well. The definition of proteinuria was a positive dip-stick or measured proteinuria over 150
mg/day. Patient and death-censored GS were evaluated as of December 2012. Seventy five KT
had follow-up data for over 15-y, 369 KT had follow-up data for over 10 years and 218 patients
had a follow-up shorter than 5 years. The data extracted from charts and local registries was
coded before analysis by one of the authors (FO), given an investigation ID-number to each
case to assure anonymous manipulation of the data. This research followed recommendations
in “Ethical principles of research in the humanities and social and behavioral sciences and pro-
posals for ethical review” and the Helsinki University Hospital local ethical committee
recommendations.
Histological samples
Protocol biopsies were obtained at a median time of 6.5 (±2.9) months (75% of them from 3 to
7 months, 21% from 7,1 to 12,9 months and the rest 4% up to 24 months). Two cores of tissue
were obtained under ultrasound guidance with an automated gun using either 16 or 18 Gauge
needles. There were no patients´ deaths or graft losses related to this procedure. The samples
were processed for routine light microscopy and stained with hematoxylin eosin, periodic acid
Schiff, Masson’s trichrome and silver-methenamine. The mean number of glomeruli was 10.4.
Immunofluorescence analysis was performed in 57.8% of the biopsies and included staining
for IgG, IgA, IgM and C3. C4d staining was available in 43% of the biopsies, and 15/388 (3.9%)
cases were positive. Histological lesions were graded by experienced nephropathologists
according to the Banff diagnostic categories [11–14]. The categories included in all versions of
the Banff classification are depicted in Table 1.
Statistical analysis
Results are expressed as the mean ± standard deviation or 95% interval confidence for the
mean. Comparison between groups was performed by either chi-square or Kruskal-Wallis test
and ANOVA for more than two groups. GS was considered the outcome variable in the present
study. Kaplan-Meier was employed to analyze variables associated with GS and log rank test
for group comparison. Cox regression was used to analyze histological diagnostic categories as
variables associated with GS. Multinomial logistic regression analysis was performed to com-
pare the odds ratio for clinical variables respecting the histological diagnostic groups. All P-val-
ues were two-tailed and significance was set at a level of 0.05. Statistical analysis was performed
using SPSS Software (version 19.0; Chicago, IL).
Results
Characteristics of the study population
Characteristics of the population are displayed in Table 2. Recipients were Caucasians, the
majority were 1st transplants from deceased donors with low HLA sensitization. Graft
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allocation was based on appropriate HLA-match, being HLA-AB-mismatches2 achieved in
70.6% of the cases and HLA-DR-mismatches1 in 93.1%. Immunosuppression at biopsy time
was the following: 91.6% were on prednisone; 18.4% were on azathioprine (AZA); 70.0% on
mofetil mycophenolate (MMF); 61.6% on cyclosporine A (CyA); 27.5% on tacrolimus (TAC)
and 7.4% were on m-Tor-inhibitor. Induction therapy was used in 22.5% of the patients
(11.3% with basiliximab and the rest with thymoglobulin). The follow-up period ranged from
0.4 to 18.5 years and mean follow-up was 7.1 y. Overall, 5-y GS was 90%, 10-year GS was 79%
and 15-year GS was 74%. Altogether 231 grafts were lost (93 returned to dialysis and 138 died
with a functioning graft). The prevalence of previous clinical AR was 23.3%. The odds ratio for
Table 1. Individual histological components included in all versions of the Banff classification.
i0—No or trivial interstitial inﬂammation (<10% of
unscarred parenchyma)
i1–10 to 25% of parenchyma inﬂamed
i2–26 to 50% of parenchyma inﬂamed i3 - > 50% of parenchyma inﬂamed
t0—No mononuclear cells in tubules t1—Foci with 1 to 4 cells/tubular cross section (or 10
tubular cells)
t2—Foci with 5 to 10 cells/tubular cross section t3—Foci with >10 cells/tubular cross section, or the
presence of at least two areas of tubular basement
membrane destruction accompanied by Í2/Í3
inﬂammation and t2 tubulitis elsewhere in the biopsy
v0- No arteritis v1- Mild-to-moderate intima arteritis in at least one
arterial cross section
v2—Severe intima arteritis with at least 25% luminal
area lost in at least one arterial cross section
v3—Transmural arteritis and/or arterial ﬁbrinoid
change and medial smooth muscle necrosis with
lymphocytic inﬁltrate in vessel
g0—No glomerutitis gl—Glomerulitis in tess than 25% of glomeruli
g2—Segmental or global glomerutitis in 25 to 75%
of glomeruli
g3—Glomerulitis (mostly global) in more than 75% of
glomeruli
ci0—Interstitial ﬁbrosis in up to 5% of cortical area ci1- Mild—interstitial ﬁbrosis in 6 to 25% of cortical
area
ci2—Moderate—interstitial ﬁbrosis in 26 to 50% of
cortical area
ci3—Severe—interstitial ﬁbrosis in >50% of cortical
area
ct0—No tubular atrophy ct1- Tubular atrophy in up to 25% of the area of
cortical tubules
ct2—Tubular atrophy involving 26 to 50% of the
area of cortical tubules
ct3—Tubular atrophy in >50% of the area of cortical
tubules
cg0—No glomerulopathy—double contours in <10%
of peripheral capillary loops in most severely
affected glomerulus
cgl—Double contours affecting up to 25% of
peripheral capillary loops in the most affected of
nonsclerotic glomeruli
cg2—Double contours affecting 26 to 50% of
peripheral capillary loops in the most affected of
nonsclerotic glomeruli
cg3—Double contours affecting more than 50% of
peripheral capillary loops in the most affected of
nonsclerotic glomeruli
cv0—No chronic vascular changes cv1- Vascular narrowing of up to 25% luminal area by
ﬁbrointimal thickening of arteries ± breach of internal
elastic lamina or presence of foam cells or occasional
mononuclear cells
cv2—Increased severity of changes described
above with 26 to 50% narrowing of vascular luminal
area
cv3—Severe vascular changes with >50% narrowing
of vascular luminal area
Deﬁnition of normal (i0, t0 and either ci = 0 OR ct = 0), borderline (no intimal arteritis, t1 and i0 or i1), acute
rejection (i2, t2 and/or v0). In 2007 was included interstitial ﬁbrosis plus tubular atrophy (IFTA) as a new
category (mild IFTA ct1 AND ci1 in <25% of the cortical area, moderate IFTA from 26% to 50% and
severe IFTA>50%). Extracted from references10 and 11.
doi:10.1371/journal.pone.0159717.t001
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15-y death censored graft loss in patients with previous clinical AR was 1.43 (95% CI 1.19–
1.72, P<0.001).
Analysis of protocol biopsies
The frequencies of each histological component of Banff are shown in Fig 1. Overall, 484 PB
(53.6%) were normal. However, among them 361 were pristine and 123 biopsies had associated
inflammatory infiltrates. IFTA was diagnosed in 257 PB (28.5%) and among them 135 had also
a variable degree of inflammation. The severity of IFTA was mild in the majority of the cases
(ci1 83.5%; ct1 86.4%). The prevalence of SCAR was 4.9% (N = 44). They were mainly T-cell
mediated and mild (55.7% grade 1a; 28.5% grade1b; 11.4% grade 2a and concomitant grade
2b) but also subclinical AMR was diagnosed in 2 cases. Biopsies with diagnosis of SCAR had
concomitantly IFTA in 37% of the cases. Borderline changes were diagnosed in 111 PB (12.3%)
and among them 47 had concomitantly IFTA. Glomerulonephritis recurrence was suspected in
one PB and confirmed in subsequent biopsies. This case was discarded to further analysis.
Impact of the histological findings on graft function and GS
Among all the individual components of Banff, inflammation had the strongest negative
impact on survival and proportional to its severity, as shown in Fig 2. The presence or the
severity of interstitial fibrosis, tubular atrophy or chronic vasculopathy did not show any
impact on GS (Log Rank P = 0.33; P = 0.57 and P = 0.71 respectively). The presence of glomer-
ulitis had a negative impact on GS only when it was associated with inflammation (P = 0.04).
Due to the notable impact of inflammatory infiltrates on GS we further split the normal and
IFTA categories into: a) normal without inflammation (i0, t0, ci0, ct0) including in this cate-
gory cases with either interstitial fibrosis (i0,t0, ci1, ct0) or tubular atrophy (i0, t0, ci0, ct1);
b) normal with inflammation (i1, t0) and those cases including either interstitial fibrosis
Table 2. Demographic data, kidney function at the time of protocol.
Recipient age, (years) mean (SD) 48.5 (12.6)
Recipient sex, male/female (%) 64/36
1st transplant (%) 86.7
Deceased donor (%) 98.2
Aetiology (%)
Diabetic nephropathy 14.8
Chronic glomerulonephritis 30.5
Polycystic kidney disease 14.0
Chronic interstitial nephritis 10.5
Other speciﬁed cause 9.4
Unknown 20.8
Time in dialysis, (months) mean (SD) 27.3 (29)
Donor age, (years) mean (SD) 44.7 (15.3)
Donor sex, male/female (%) 60 /40
Cold ischemia time, (hours) mean (SD) 19.5 (5.5)
Panel reactive antibodies <10% 89.9%
Delayed graft function, Yes/No (%) 26.4 / 73.6
AB-mismatches (%) 0/1/2/3/4 6/24/41/22/7
DR-mismatches (%) 0/1/2 33.7 / 59.4 / 6.9
Clinical acute rejection previous to PB (%) 23.3
Mean serum creatinine, (μmol/L) mean (SD) 119.6 (35)
doi:10.1371/journal.pone.0159717.t002
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(i1, ci1, ct0) or tubular atrophy (i1, ci0, ct1); c) IFTA without inflammation (i0, t0, ci1
and ct1) and d) IFTA with inflammation (i1, t0, ci1 and ct1). Borderline and SCAR
were defined according to Banff and compared to the previously mentioned categories.
The mean creatinine concentration in plasma at the time of the PB was 113 umol/L (95% CI
110–117) in PB diagnosed as normal without inflammation, while in those normal with inflamma-
tion was 119 umol/L (95% CI 112–126). In borderline cases the mean creatinine concentration
was 119 umol/L (95% CI 110–127). The differences between these subgroups were not statistically
different. Even for the cases diagnosed with SCAR the mean creatinine concentration was 128
umol/L (95%CI 109–149) and the P value was 0.065. The differences in graft function reached the
statistical level of significance only in the cases of normal biopsies without inflammation compared
with both IFTA without inflammation (P = 0.002) and IFTA with inflammation (P = 0.007), being
the creatinine concentration in cases with IFTA without inflammation 127 umol/L (95%CI 121–
134) and 126 umol/L (95%CI 120–131) if IFTA was associated with inflammation.
The split of normal PB and IFTA according to the presence of inflammation showed a strong
impact on both 15-y GS and 15-y DCGS, as shown in Fig 3. The best survival was observed in the
groups without inflammation (both normal histology and IFTA). The worst GS was seen in cases
of SCAR, but borderline category had also a weak survival comparable to normal with inflamma-
tion and IFTA with inflammation. The difference in 15-y DCGS between “normal without
inflammation” and “normal with inflammation” was statistically significant (P = 0.01)
We calculated the risk for graft loss taking as variables the five groups in which the PB were
divided. The reference group was “normal w/o inflammation”. In the multivariate analysis the
risk for graft lost at 15 years was significantly increased in case of a normal biopsy with inflam-
mation and rejection. The hazard ratios are depicted in Table 3.
Factors predicting survival
For this analysis we unified borderline and SCAR into “rejection” and compared to the other
groups. As shown in Table 4, PRA percentage, CIT occurrence or DGF or male sex did not
Fig 1. Frequency of the lesions diagnosed in PB.
doi:10.1371/journal.pone.0159717.g001
Inflammation in Protocol Biopsies
PLOS ONE | DOI:10.1371/journal.pone.0159717 August 17, 2016 6 / 14
differ among categories. Both donor age and time to PB were higher in IFTA, as expected. We
observed a higher number of HLA AB-mismatches in IFTA without inflammation and rejec-
tion groups, which was in both cases significantly higher compared to normal with inflamma-
tion. HLA DR-mismatches occurred more frequently in all subgroups with inflammation
infiltrates (P<0.001). In a similar way, previous episode of AR was more frequent in all the sub-
groups with inflammation. There was a considerable increase in the number of patients devel-
oping proteinuria during the follow-up, being those with SCAR and borderline the subgroups
with the highest increase from 14.8% to 37.7% of the patients. Notably, the “normal with
inflammation” subgroup also experienced a considerable increase of proteinuria, from 8.2 to
24.4%. The patients with pristine normal biopsies had the least proteinuria both at PB
(P<0.001) and at the end of the follow-up (P = 0.001). To evaluate the impact of each of these
Fig 2. Impact of inflammation severity on death censored graft survival.
doi:10.1371/journal.pone.0159717.g002
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statistically significant variables on graft survival we performed a multinomial regression anal-
ysis using the “normal without inflammation” as the reference group. The results are exposed
in Table 5. Of notice, a previous AR episode and HLA DR-mismatch increased the odds of hav-
ing a “normal PB with inflammation” (OR 2.67 and 2.18, respectively). The presence of pro-
teinuria at BP increased the odds of having a PB with IFTA, SCAR or borderline diagnosis. A
HLA DR-mismatch also increased the odds of having a PB with rejection (OR 1.67) or IFTA
with inflammation (OR 1.79).
Changes in the immunosuppression after PB
In all, 81% of the patients were on triple immunosuppressive treatment at biopsy. CyA, MMF
and steroids was the most common combination (40%), followed by TAC, MMF and steroids
(23%). Only 4% were on TAC, AZA and steroids and 14% on CyA, AZA and steroids. The
choice of TAC over CyA was influenced by the recipient higher immunological risk (re-
Fig 3. Graft survival of Banff categories split regarding the presence of inflammation. In panel A: 15-y graft survival. In panel B: 15-y death-censored
graft survival.
doi:10.1371/journal.pone.0159717.g003
Table 3. Cox regression was use for investigating the effect of histological categories diagnosis upon 15-y death censored graft survival.
Covariates Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Normal WITH inﬂammation 1.96 1.37–2.55 0.023 2.01 1.42–2.59 0.018
IFTA w/o inﬂammation 0.94 0.17–1.71 0.888 - - - - - -
IFTAWITH inﬂammation 1.58 0.74–2.09 0.164 - - - - - -
Rejection 1.819 1.27–2.37 0.030 1.78 1.22–2.33 0.038
The reference group was “normal without inﬂammation”, being the other categories´ hazard ratios calculated ﬁrst in all categories and afterwards keeping
those statistically signiﬁcant from the univariate analysis.
doi:10.1371/journal.pone.0159717.t003
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transplantation, high PRA, HLA mismatches) and vintage (change in the choice of CNI
towards TAC in the recent era).
From 553 patients who were on CyA at PB, 34 (6.1%) were switched to TAC by the end of
the 2nd year. Steroids were discontinued by the end of the 2nd year in 218 patients under CyA
treatment (39.4%). TAC was used by 246 patients at PB and 115 of them (46.7%) were off ste-
roids by the 2nd year. Overall, after the PB steroids were discontinued in 51.1% of the patients
with normal PB without inflammation, while the figures for the other groups were 48.4% in
normal with inflammation, 35% for IFTA without inflammation, 23.9% for IFTA with inflam-
mation and 27.2% for the rejection group (P<0.001). The continuation of steroids over the 2nd
year after did not have a statistical significant impact on the graft survival in any of the groups
(P = 0.29). The modifications in the immunosuppression were not associated with the outcome
in any of the four histological groups.
Table 4. Multinomial logistic regression analysis was performed to compare the odds ratio for demographic, immunological, clinical and biochem-
ical variables respecting the 5 histological diagnostic groups.
Normal w/o inﬂammation
N = 361
Normal w/ inﬂammation
N = 123
IFTA w/o inﬂammation
N = 122
IFTA w/ inﬂammation
N = 297
Rejection
N = 160
P
Donor age (years)mean (95%CI)
43.8 (42.2–45.4) 43.2 (40.5–45.9) 50.0 (47.3–52.6) 45.6 (43.2–47.9) 43.5 (40.0–
46.1)
P< 0.01 c-a,b,e
Panel reactive antibodies (%)mean (95%CI)
4.5 (2.9–6.2) 4.8 (1.9–7.7) 3.2 (1.4–5.1) 5.1 (2.2–7.9) 2.9 (1.2–4.6) P = 0.62
Cold ischemia time (hours)mean (95%CI)
19.6 (19.1–20.2) 18.9 (17.9–19.9) 19.6 (18.5–20.6) 19.9 (19.2–20.7) 19.1 (18.1–
19.9)
P = 0.44
Time to biopsy (months)mean (95%CI)
6.3 (6.0–6.5) 6.5 (6.0–7.0) 7.1 (6.4–7.8) 7.4 (6.9–8.0) 5.9 (5.5–6.3) P = 0.01 c-e
P< 0.01 d-a,e
Plasma creatinine at biopsy (SD)
113.6 (32.4) 119.5 (37.7) 127.5 (37.7) 125.8 (34.6) 124.1 (28.1) P = 0.004 a-c
P = 0.013 a-d
Donor sex (male) N = 580 (64.2%)
238 (64,2) 77 (62.6) 82 (67.2) 86 (63.7) 97 (59.9) P = 0.66
Delayed graft function (yes) N = 237 (26.4%)
85 (23.7) 38 (30.9) 36 (29.8) 46 (34.1) 32 (19.8) P = 0.35
HLA AB-mismatches >2 N = 266 (29.5%)
103 (28.5) 22 (17.9) 46 (37.7) 29 (21.5) 66 (40.7) P<0.001 b-c.e
HLA DR-mismatches >0 N = 601 (66.6%)
212 (58.7) 96 (78.0) 75 (61.5) 101 (74.8) 117 (72.2) P<0.001 a—b,d,e
P<0.001 b,c
Clinical acute rejection previous to PB (yes) N = 210 (23.3%)
48 (13.3) 40 (32.5) 19 (15.6) 45 (33.3) 58 (35.8) P<0.001 a- b,d,e
P<0.001 b-c
Proteinuria at biopsy (yes) N = 87 (9.7%)
18 (5.1) 10 (8.2) 18 (15.0) 17(12.6) 24 (14.8) P<0.001 a- c,d,e
Proteinuria during follow-up (yes) N = 215 (24%)
63 (17.6) 30 (24.4) 29 (24) 32 (23.7) 61 (37.7) P = 0.001 a-e
Rejection category includes borderline. Presence of proteinuria meant a positive dip-stick or measured proteinuria over 150 mg/day. a) Normal without
inﬂammation. b) Normal with inﬂammation. c) IFTA without inﬂammation. d) IFTA withy inﬂammation. e) Rejection.
doi:10.1371/journal.pone.0159717.t004
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Discussion
The most important finding in this study was that kidney PB with trivial inflammation between
11–25% of unscarred parenchyma diagnosed otherwise as normal had a reduced long term sur-
vival comparable to PB with rejection. Our results highlight the fact that “innocent”mild infil-
trates in otherwise normal biopsies may have a deleterious effect and they should be
considered relevant in clinical practice. We observed that inflammation is a frequent finding in
protocol biopsies, affecting 45% of them. Furthermore, of the 484 biopsies diagnosed as nor-
mal, 25% showed inflammation. In a previous study focused also on PB obtained at 1 to 4
months after KT the frequency of inflammation was 19%. These patients had more IFTA in a
control biopsy obtained after one year compared to those without inflammation. [15] Mengel
et al came to a similar conclusion in their study: if the infiltrates persisted in successive biopsies
graft prognosis was worse, although the diagnosis of inflammation included foci of inflamma-
tion in scarred areas. [16] The DeKAF study also suggested that the inclusion of inflammation
in scarred areas in the assessment of biopsies may provide better prognostic information. [17]
In our material the PB were classified using the latest version of the Banff classification contem-
porary with the time when the PB was taken, where inflammation was scored only in non-
scarred areas. We might suggest that using the total inflammation score proposed recently by
the Banff working group the frequency of truly normal biopsies could have been even lower.
Table 5. Multinomial logistic regression analysis results for prediction the probabilities of each histological categories given a set of independent
variables selected from the logistic regression analysis.
B Sig. OR 95%CI for OR
Lower Bound Upper Bound
Normal with inﬂammation
Donor age – 0.002 0.785 0.99 0.98 1.01
Previous AR 0.985 <0.001 2.67 1.61 4.44
Proteinuria at PB 0. 590 0.161 1.80 0.794 4.12
HLA AB-mismatch >2 – 0.464 0.085 0.62 0.37 1.06
HLA DR-mismatch1 0.780 0.002 2.18 1.33 3.57
SCAR + borderline
Donor age 0.000 0.95 1.00 0.99 1.02
Previous AR 1.256 <0.001 3.51 2.20 5.59
Proteinuria at PB 1.033 0.004 2.72 1.38 0.53
HLA AB-mismatch >2 0.642 0.002 1.89 1.25 2.86
HLA DR-mismatch1 0.515 0.017 1.67 1.09 2.25
IFTA w/o inﬂammation
Donor age 0.027 <0.001 1.03 1.01 1.04
Previous AR 0,273 0.377 1.31 0.76 2.41
Proteinuria at PB 0,911 0.013 2.48 1.21 5.08
HLA AB-mismatch >2 0.401 0.081 1.49 0.95 2.34
HLA DR-mismatch1 0.088 0.692 1.09 0.71 1.69
IFTA with inﬂammation
Donor age 0.008 0.253 1.01 0.99 1.02
Previous AR 1.099 <0.001 3.00 1.84 4.89
Proteinuria at PB 0.954 0.009 2.59 1.26 5.32
HLA AB-mismatch >2 -0.282 0.256 0.75 0.46 1.22
HLA DR-mismatch1 0.583 0.012 1.79 1.13 2.82
Normal without inﬂammation was used as reference category. AR: acute rejection; PB: protocol biopsy. OR: odds ratio. In bold statistically signiﬁcant values.
doi:10.1371/journal.pone.0159717.t005
Inflammation in Protocol Biopsies
PLOS ONE | DOI:10.1371/journal.pone.0159717 August 17, 2016 10 / 14
Even though we do not have serial biopsies to evaluate the evolution of the inflammatory infil-
trates, we found evidence that the mere presence of inflammation in a well-functioning graft
may provide prognostic value to the physician.
The inflammation in normal biopsies was associated even with a worse prognosis than
IFTA alone. This observation is in agreement with previous reports where mild fibrosis did not
affect the prognosis compared to normal biopsies, contrarily to IFTA with inflammation. [18]
In the past years the Banff classification gave a great emphasis to interstitial fibrosis and tubular
atrophy, as it has been linked to graft dysfunction. [19,20] Our data suggests that IFTA,
although associated with elevated serum creatinine, does not necessarily worsen the kidney
graft prognosis, but the most relevant histological risk factor is inflammation. Our results
could be partially affected by the mild degree of interstitial fibrosis and tubular atrophy
observed in our material. Both inflammation and IFTA are quite unspecific markers since they
can be associated with immunological damage but also with non- immunological insults like
calcineurin inhibitor toxicity and infection.
The detrimental effect of previous AR episode and persistent inflammation on protocol
biopsies obtained after the 1st year from transplantation has been very well described before
[5,8,15,19,21–24]. In the case of proteinuria, the incidence after 1 year from transplantation
varies between 11 and 45%. [25] Others suggested that proteinuria is detrimental only when
associated to AR. [25–27] We observed that the prevalence of proteinuria at the time of the
biopsy was 9.5% when we defined a positive value as low as over 150 mg/day or 1+ positive
urine dip-stick. This low threshold for proteinuria is the reason why 5% of patients with nor-
mal biopsies had proteinuria, although the lowest. The presence of inflammation increased the
frequency of proteinuria in our study cohort also in “normal with inflammation”, and IFTA.
This is in dissidence with the previous reports in the literature associating it mostly to rejection.
Proteinuria increased remarkably during follow-up in all groups. Again, the lowest number of
patients with proteinuria belonged to the “normal w/o inflammation” group and the highest
number of patients to the group “rejection”. Our results are in concordance with those report-
ing that the persistence or appearance of proteinuria after KT is a marker of graft damage and
related to worse GS [28–30] and patient survival. [31]
One of the most argued clinical issues in PB policy is why take a biopsy from a well-func-
tioning graft. It is well known that serum creatinine concentration is a poor indicator of graft
histology. [32] We analyzed the graft function in each histological category and we found that
patients diagnosed with IFTA had a statistically higher creatinine than all the other groups.
These patients received grafts from older donors, raising the possibility that, at least partly, the
chronic changes came along with the donor. Unfortunately, we do not have an implant biopsy
from all our patients to focus on this aspect. Remarkably, normal and borderline cases had a
similar creatinine concentration, while SCAR and IFTA cases showed a higher creatinine con-
centration. This highlights the unreliability of serum creatinine as a surrogate of histology.
Along with a decline in the incidence of previous clinical AR, SCARs have also become
more infrequent. The incidence of SCAR and borderline changes is our study was 4.9% and
12.3%. Many researchers combined borderline changes with SCAR due to a comparable GS
[18,33] and similar molecular phenotyping [34] of both entities. Based on these considerations
we decided to join both entities for a group comparison with normal and IFTA. We analyzed
which variables could predict the histological categories and we did not find CIT, DGF, PRA or
male gender to be relevant. Although in previous studies biopsies from patients on CyA show-
ing more inflammation than those on TAC [23], we decided not include CNI-choice in the
multivariate analysis due to the fact that the choice of CNI was not random and it was influ-
enced by the patient´s immunological risk and vintage. On the contrary, donor age, proteinuria
at biopsy, HLA DR-mm1, HLA AB-mm>2, time from transplantation and previous AR
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episode were the covariates that might discriminate patients at a higher risk for abnormal his-
tology. These results could help selecting patients who could eventually benefit from a PB,
avoiding this procedure in those with no risk factors.
Major limitations of our study are its retrospective design, the lack of donor specific anti-
body monitoring and adherence to medication. It´s worth to highlight that the role of non-
adherence to medication was not studied during this study period, and data about its possible
impact on the appearance of donor specific antibodies is not available. Finally follow-up biop-
sies were not available to ascertain the effect of late AR episodes. The high number of patients
followed up for up to 18 years after transplantation gives a particular strength to the analysis.
In conclusion, this study showed that 60% of the PB were pathologic. The most relevant
abnormality was the presence of inflammation, which was the main factor affecting GS. Partic-
ularly trivial inflammation affecting otherwise normal biopsies was associated to poor progno-
sis. A previous AR episode, the presence of even low grade proteinuria and DR mismatch were
the variables that predicted the best an abnormal biopsy. A new look at the inflammation scor-
ing in the Banff classification might contribute to a better stratification of patients at risk of
graft loss.
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